Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: riboflavin Clear all
Completed Phase 1 Interventional

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
Other · Device · Dietary Supplement + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 22, 2026, 2:35 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

NCT05027295
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
riboflavin ophthalmic solution
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 22, 2026, 2:35 PM EDT
Not listed Phase 3 Interventional

Corneal Cross-Linking Comparing Variables

NCT02095730
View directory record Official record
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional

CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01956474
View directory record Official record
Conditions
Keratoconus
Interventions
Theralight crosslinking and Riboflavin
Other
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Miami, Florida • Atlanta, Georgia • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Phase 3 Interventional Results available

Safety Study of the VEGA UV-A System to Treat Ectasia

NCT01398839
View directory record Official record
Conditions
Ectasia
Interventions
VEGA UV-A Illumination System, Riboflavin
Device · Drug
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Atlanta, Georgia • Bloomington, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Mitochondrial Cocktail for Gulf War Illness

NCT02804828
View directory record Official record
Conditions
Gulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorders
Interventions
Individualized mitochondrial cocktail, Placebo
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
48 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01972854
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Irvine, California • San Diego, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Withdrawn Not applicable Interventional

Monitoring the Effects of Probiotic Supplementation in Immunocompromised Kidney Transplanted Subjects

NCT05102461
View directory record Official record
Conditions
Diarrhea Caused by Drug, Dysbiosis
Interventions
Florajen Digestion Supplementation, Placebo Supplementation
Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Recruiting Phase 2Phase 3 Interventional

Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia

NCT07841470
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Soy Isoflavones and Breast Cancer Risk Reduction

NCT00204490
View directory record Official record
Conditions
Breast Cancer
Interventions
isoflavones, carbohydrate
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 42 Years · Female only
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Whole Foods Supplementation on Cognition

NCT01672359
View directory record Official record
Conditions
Sub-optimal Cognitive Function, Sub-optimal Immune Function
Interventions
Ginkgo Synergy® and Choline, OPC Synergy® and Catalyn, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
60 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 22, 2026, 2:35 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298
View directory record Official record
Conditions
Keratoconus, Ectasia, Corneal Ectasia
Interventions
UV-X Light, Riboflavin
Device · Drug
Lead sponsor
Mercy Center for Corrective Eye Surgery
Other
Eligibility
14 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
McHenry, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

NCT02622386
View directory record Official record
Conditions
Psoriasis
Interventions
Riboflavin, Placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Quetiapine on Marijuana Withdrawal and Relapse

NCT00743366
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Marijuana, Quetiapine, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04177082
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Open Label Study: Treatment of ALS Fatigue With PolyMVA

NCT04557410
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PolyMVA
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Completed No phase listed Observational

Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia

NCT01726283
View directory record Official record
Conditions
Fruste Keratoconus, Risk of Ectasia
Interventions
Corneal Cross-Linking, Riboflavin
Device · Drug
Lead sponsor
Cxlusa
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals

NCT00218062
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
D-Amphetamine 30mg, D-Amphetamine 60mg, Modafinil 200mg, Modafinil 400mg, Therapy, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Alii Supplement Study

NCT07271316
View directory record Official record
Conditions
Nutrient Deficiency, Happiness, Digestive Health, Vulnerability to Disease, Mood Swings, Energy
Interventions
Alii Supplement
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 2:35 PM EDT
Withdrawn Not applicable Interventional

A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs

NCT00037063
View directory record Official record
Conditions
HIV Infections
Interventions
Thiamine hydrochloride, Riboflavin, Ascorbic acid, Vitamin E
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Denver, Colorado • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 22, 2026, 2:35 PM EDT
Not yet recruiting Not applicable Interventional

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

NCT04584125
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 22, 2026, 2:35 PM EDT